Glenn Jay Jaffe

I have an active basic and clinical research program. I have been principal investigator on several funded clinical studies including investigations of an oral ganciclovir prodrug to treat CMV retinitis and a study to determine the safety of a cyclosporine sustained drug delivery implant in the treatment of uveitis. I am principal investigator of an ongoing multicenter trial of a fluocinolone sustained drug delivery implant to treat patients with severe uveitis and a trial of this same implant to treat diabetic macular edema. Recently, I have investigated the use of ultrasonography and optical coherence tomography to diagnose macular edema in a variety of ocular diseases. I have maintained an ongoing basic research program to test the hypothesis that cytokines are important in the development of proliferative vitreoretinopathy, an important intraocular wound healing disorder. Education: I am actively involved in resident and fellow education. I give lectures to residents and fellows on a variety of topics related to uveitis and vitreoretinal diseases and train fellows to perform vitreoretinal surgery. I train post-doctoral students and medical students to conduct clinically relevant research. I serve as a mentor for the Duke third year medical school research program. I have served on a yearly basis as course faculty at many national and international meetings.

Current Appointments & Affiliations

Robert Machemer M.D. Distinguished Professor of Ophthalmology · 2013 - Present Ophthalmology, Vitreoretinal Diseases & Surgery, Ophthalmology

Professor of Ophthalmology · 1998 - Present Ophthalmology, Vitreoretinal Diseases & Surgery, Ophthalmology

Chief, Division of Retinal Ophthalmology · 2008 - Present Ophthalmology, Vitreoretinal Diseases & Surgery, Ophthalmology

In the News

Published September 8, 2016

Humira Provides Effective, Non-Steroid Alternative for Eye Inflammation

View All News

Recent Publications

Standardization of Imaging Criteria for Detecting Macular Fibrosis in Neovascular Age-Related Macular Degeneration.

Journal Article Ophthalmol Sci · February 2026 PURPOSE: To evaluate conventional imaging modalities for detecting fibrosis in neovascular age-related macular degeneration (nAMD) and to develop a standardized diagnostic workflow. DESIGN: Systematic discussion and grading exercise assessing multiple imag ... Full text Link to item Cite

Bilateral Harada-like reaction with bacillary layer detachment after treatment of metastatic signet ring cell carcinoma with pembrolizumab.

Journal Article Retin Cases Brief Rep · December 31, 2025 PURPOSE: To present a case of bilateral severe Harada-like reaction with bacillary layer detachments secondary to pembrolizumab therapy for metastatic signet ring cell carcinoma. METHODS: Case report. RESULTS: A 33-year-old black male with a medical histor ... Full text Link to item Cite

Best Practices for High-Quality Anterior Segment Optical Coherence Tomography Imaging of Eyes with the Port Delivery Platform Implant.

Journal Article Diagnostics (Basel) · December 5, 2025 Background/Objectives: Anterior segment optical coherence tomography (AS-OCT) is a non-invasive imaging modality used to evaluate anterior segment features. This report aims to inform clinicians of best practices to obtain high-resolution AS-OCT images of ... Full text Link to item Cite

View All Publications

Recent Grants

A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of ixoberogene soroparvovec (Ixo-vec) in Participants with Neovascular Age-Related Macular Degeneration (AQUARIUS)

ResearchPrincipal Investigator · Awarded by Adverum Biotechnologies, Inc · 2026 - 2032

A Ph 4, Multicenter, Open-label Study to Evaluate Long-term Safety and Efficacy of Revakinagene Taroretcel-Lwey (NT-501) Previously Implanted in a Ph 1, Ph 2, or Ph 3 Clinical Study and to Evaluate NT-501 Implanted in Participants...

ResearchPrincipal Investigator · Awarded by Neurotech Pharmaceuticals, Inc. · 2025 - 2030

A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment- Experienced Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD)

ResearchPrincipal Investigator · Awarded by Adverum Biotechnologies, Inc · 2022 - 2029

View All Grants

Education, Training & Certifications

University of California San Francisco, School of Medicine · 1983 M.D.